Together, these findings indicate that an alternate HIF2α heterodimer containing the circadian partner BMAL1 contributes to HIF2α activity, growth, and sensitivity to HIF2α antagonist drugs in ccRCC cells. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.